Lomvastomig is a bispecific antibody targeting PD-1 and TIM-3 designed to reverse T-cell exhaustion and enhance antitumor immunity. Preclinical studies demonstrated potent antitumor activity, supporting advancement into clinical development. The Phase I study showed an acceptable safety profile, evidence of pharmacodynamic activity, and preliminary antitumor responses in patients with advanced solid tumors.
Dual PD-1 and TIM-3 blockade enhanced antitumor activity in preclinical models and supported clinical development of lomvastomig. Clinical evaluation demonstrated pharmacodynamic activity consistent with immune activation and checkpoint inhibition.
Human PD-1 / Human TIM-3 double Knockin mouse — genOway-developed, challenged with MC38 murine colon adenocarcinoma cells for preclinical efficacy studies
Immuno-oncology, immune checkpoint inhibition, T-cell exhaustion, PD-1 targeting, TIM-3 targeting, bispecific antibodies, solid tumor immunotherapy
Human PD-1 Knockin, Human TIM-3 Knockin, double-humanized checkpoint model, MC38 syngeneic tumor challenge, preclinical efficacy evaluation, immune activation profiling
From model design to experimental results
Featured in 600+ scientific articles
Collaboration with 17 Top Pharmas,
170+ Biotechs and 380+ Academic Institutions
Generated with biopharma partners and in-house
and guaranteed freedom to operate
Models with certified health status from professional breeders in US and Europe
